

CITATION REPORT

List of articles citing

Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension

DOI: 10.1177/1753465812463627

Therapeutic Advances in Respiratory Disease, 2013, 7, 39-49.

Source: <https://exaly.com/paper-pdf/56423600/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
13	Pediatric pulmonary arterial hypertension. <i>Current Hypertension Reports</i> , 2013 , 15, 606-13	4.7	4
12	Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. <i>Clinics in Chest Medicine</i> , 2013 , 34, 811-24	5.3	4
11	Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling. <i>Cell Death and Disease</i> , 2014 , 5, e1544	9.8	26
10	Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. <i>Biochemical Pharmacology</i> , 2014 , 89, 86-98	6	21
9	Pulmonary arterial hypertension: a rare disease that encourages the development of multiple treatments. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 1137-1145	1.1	2
8	Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension. <i>Pharmacoeconomics</i> , 2016 , 34, 751-70	4.4	22
7	Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 6622-6637	8.3	23
6	A review of therapeutic agents for the management of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2017 , 11, 46-63	4.9	8
5	3D-QSAR modeling of Phosphodiesterase-5 inhibitors: evaluation and comparison of the receptor- and ligand-based alignments. <i>Medicinal Chemistry Research</i> , 2019 , 28, 820-830	2.2	1
4	Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment. <i>European Journal of Pharmaceutical Sciences</i> , 2019 , 133, 275-286	5.1	7
3	Therapeutic potential of phosphodiesterase inhibitors in the treatment of osteoporosis: Scopes for therapeutic repurposing and discovery of new oral osteoanabolic drugs. <i>European Journal of Pharmacology</i> , 2021 , 899, 174015	5.3	2
2	Free energy perturbation (FEP)-guided scaffold hopping.. <i>Acta Pharmaceutica Sinica B</i> , 2022 , 12, 1351-1365	3.5	1
1	Inhibition by tadalafil of contractility of isolated nonpregnant human myometrium. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2016 , 7, 177-181	0.2	2